Valiant Laboratories Ltd
Incorporated in 1980, Valiant Laboratories
Ltd manufactures and deals in Pharmaceuticals and speciality chemicals[1]
- Market Cap ₹ 354 Cr.
- Current Price ₹ 65.1
- High / Low ₹ 127 / 63.9
- Stock P/E 51.9
- Book Value ₹ 58.4
- Dividend Yield 0.00 %
- ROCE -1.05 %
- ROE -1.40 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Stock is trading at 1.11 times its book value
- Company is expected to give good quarter
Cons
- Company has a low return on equity of 4.66% over last 3 years.
- Earnings include an other income of Rs.2.84 Cr.
- Company has high debtors of 197 days.
- Working capital days have increased from 132 days to 194 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|
| 182 | 292 | 334 | 182 | 133 | 190 | |
| 132 | 249 | 299 | 190 | 138 | 183 | |
| Operating Profit | 50 | 42 | 35 | -8 | -5 | 7 |
| OPM % | 27% | 15% | 11% | -5% | -4% | 4% |
| 1 | 2 | 5 | 10 | 5 | 3 | |
| Interest | 2 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 3 | 2 | 2 | 2 | 2 | 2 |
| Profit before tax | 47 | 42 | 38 | -1 | -1 | 7 |
| Tax % | 35% | 34% | 24% | -145% | 49% | |
| 31 | 28 | 29 | 0 | -2 | 7 | |
| EPS in Rs | 13.48 | 7.13 | 0.06 | -0.40 | 1.26 | |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -23% |
| TTM: | 70% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 158% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -40% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 5% |
| Last Year: | -1% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|
| Equity Capital | 10 | 16 | 33 | 43 | 43 | 54 |
| Reserves | 78 | 55 | 68 | 193 | 191 | 263 |
| 1 | 61 | 60 | 60 | 60 | 0 | |
| 17 | 49 | 52 | 28 | 23 | 31 | |
| Total Liabilities | 106 | 182 | 213 | 325 | 317 | 349 |
| 20 | 22 | 30 | 32 | 30 | 29 | |
| CWIP | 0 | 1 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 34 | 119 | 165 | 206 |
| 87 | 158 | 149 | 174 | 122 | 114 | |
| Total Assets | 106 | 182 | 213 | 325 | 317 | 349 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| 9 | 2 | 23 | 49 | -22 | |
| -17 | -12 | -21 | -183 | 25 | |
| 11 | 6 | -2 | 136 | -0 | |
| Net Cash Flow | 4 | -4 | 0 | 2 | 3 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Debtor Days | 85 | 139 | 97 | 92 | 197 |
| Inventory Days | 18 | 25 | 17 | 22 | 12 |
| Days Payable | 37 | 72 | 62 | 54 | 61 |
| Cash Conversion Cycle | 66 | 91 | 52 | 60 | 149 |
| Working Capital Days | 102 | 109 | 106 | 97 | 194 |
| ROCE % | 38% | 26% | -2% | -1% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
13 Nov - Copy of Newspaper Publication for Financial Results of Q2 FY 2025-26.
-
Board Comments On The Communication Received From The Stock Exchanges
11 Nov - Board comments on Reg 29 non‑compliance; ₹11,800 fines paid Aug 20, 2025; Rights Issue meeting July 15, 2025.
-
Announcement under Regulation 30 (LODR)-Monitoring Agency Report
11 Nov - Monitoring agency reports no deviation; INR 8,146.88 lakh rights issue proceeds largely utilized by Sep 30, 2025.
-
Audited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended September 30, 2025.
11 Nov - Board approved audited standalone and consolidated results for quarter/half-year ended 30 Sep 2025; auditor report attached.
-
Board Meeting Outcome for Audited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended September 30, 2025.
11 Nov - Board approved audited standalone and consolidated results for quarter and half-year ended 30 Sep 2025.
Business Overview:[1][2]
VLL is in the active pharmaceutical ingredient manufacturing business. It manufactures finished dosage forms of paracetamol API viz. Tablets, Capsules, and Other medications. Paracetamol API is a key ingredient used to treat a variety of conditions including Headache, Arthritis, Muscle Aches, Toothache, Backache, Cold, and Fever